No Dramatic Changes Planned as Newly Merged Thermo Fisher Focuses Near-Term on Innovation | GenomeWeb
Thermo Fisher Scientific has no short-term plans to dramatically change its newly combined sales force or product portfolio, a company executive told BioCommerce Week following European approval for the firms’ $10.6 billion merger last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.